Roche brings 7-minute lung cancer shot to India
New Delhi: Roche Pharma India has launched the country’s first injectable immunotherapy for lung cancer, allowing patients to…
Roche India Launches First Under-the-Skin Lung Cancer Therapy
This new way of giving Tecentriq shows Roche’s focus on improving cancer treatment in India. The faster under-the-skin…
Roche Launches Under-the-Skin Lung Cancer Treatment in India: Rediff Moneynews
Roche introduces Tecentriq SC, a subcutaneous lung cancer treatment in India, reducing hospital time. Faster, convenient cancer care…
Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancer
Roche Pharma on Thursday launched Tecentriq (atezolizumab), the country’s first subcutaneous immunotherapy for lung cancer — an under-the-skin…
Prefillable Glass Syringes Market in Switzerland | Report – IndexBox
This report is an independent strategic market study that provides a structured, commercially grounded analysis of the market…
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
F. Hoffmann-La Roche Ltd A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of…